Etanercept

Tsutomu Takeuchi, Koichi Amano

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Etanercept is a protein comprised of the extracellular domains of two TNF receptors attached to a Fc portion of an IgG. Etanercept was approved for not only reducing signs and symptoms but inhibiting of structural damage in patients with active RA who had an inadequate response to one or more DMARDs. Moreover, combination therapy with methotrexate will be attractive for severely active patients. The proportion of patients who have discontinued therapy due to adverse events is approximately 4%. Etanercept has not raised the risk for serious infections(0.04/patient-year) as well as malignancies. There are sporadic case reports of aplastic anemia, demyelination, lupus-like conditions, which are not significant so far. Etanercept may contribute rheumatologists to manage patients with RA.

Original languageEnglish
Pages (from-to)2390-2396
Number of pages7
JournalNippon rinsho. Japanese journal of clinical medicine
Volume60
Issue number12
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Antirheumatic Agents
Aplastic Anemia
Tumor Necrosis Factor Receptors
Demyelinating Diseases
Methotrexate
Signs and Symptoms
Immunoglobulin G
Etanercept
Therapeutics
Infection
Neoplasms
Proteins
Rheumatologists

Cite this

Etanercept. / Takeuchi, Tsutomu; Amano, Koichi.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 60, No. 12, 2002, p. 2390-2396.

Research output: Contribution to journalArticle

Takeuchi, T & Amano, K 2002, 'Etanercept', Nippon rinsho. Japanese journal of clinical medicine, vol. 60, no. 12, pp. 2390-2396.
Takeuchi, Tsutomu ; Amano, Koichi. / Etanercept. In: Nippon rinsho. Japanese journal of clinical medicine. 2002 ; Vol. 60, No. 12. pp. 2390-2396.
@article{420d5b991e36487c91163ad60996338e,
title = "Etanercept",
abstract = "Etanercept is a protein comprised of the extracellular domains of two TNF receptors attached to a Fc portion of an IgG. Etanercept was approved for not only reducing signs and symptoms but inhibiting of structural damage in patients with active RA who had an inadequate response to one or more DMARDs. Moreover, combination therapy with methotrexate will be attractive for severely active patients. The proportion of patients who have discontinued therapy due to adverse events is approximately 4{\%}. Etanercept has not raised the risk for serious infections(0.04/patient-year) as well as malignancies. There are sporadic case reports of aplastic anemia, demyelination, lupus-like conditions, which are not significant so far. Etanercept may contribute rheumatologists to manage patients with RA.",
author = "Tsutomu Takeuchi and Koichi Amano",
year = "2002",
language = "English",
volume = "60",
pages = "2390--2396",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "12",

}

TY - JOUR

T1 - Etanercept

AU - Takeuchi, Tsutomu

AU - Amano, Koichi

PY - 2002

Y1 - 2002

N2 - Etanercept is a protein comprised of the extracellular domains of two TNF receptors attached to a Fc portion of an IgG. Etanercept was approved for not only reducing signs and symptoms but inhibiting of structural damage in patients with active RA who had an inadequate response to one or more DMARDs. Moreover, combination therapy with methotrexate will be attractive for severely active patients. The proportion of patients who have discontinued therapy due to adverse events is approximately 4%. Etanercept has not raised the risk for serious infections(0.04/patient-year) as well as malignancies. There are sporadic case reports of aplastic anemia, demyelination, lupus-like conditions, which are not significant so far. Etanercept may contribute rheumatologists to manage patients with RA.

AB - Etanercept is a protein comprised of the extracellular domains of two TNF receptors attached to a Fc portion of an IgG. Etanercept was approved for not only reducing signs and symptoms but inhibiting of structural damage in patients with active RA who had an inadequate response to one or more DMARDs. Moreover, combination therapy with methotrexate will be attractive for severely active patients. The proportion of patients who have discontinued therapy due to adverse events is approximately 4%. Etanercept has not raised the risk for serious infections(0.04/patient-year) as well as malignancies. There are sporadic case reports of aplastic anemia, demyelination, lupus-like conditions, which are not significant so far. Etanercept may contribute rheumatologists to manage patients with RA.

UR - http://www.scopus.com/inward/record.url?scp=0036985695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036985695&partnerID=8YFLogxK

M3 - Article

C2 - 12510367

AN - SCOPUS:0036985695

VL - 60

SP - 2390

EP - 2396

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 12

ER -